+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.

Age: 18Years - 130YearsAll GendersPhase 3
709 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ZL-1310 compared to the Investigators Choice Therapy in participants with relapsed small cell lung cancer SCLC. This phase 3 study aims to understand how well ZL-1310, a DLL3 antibody-drug conjugate, works against SCLC that has returned after initial treatment, with a focus on response rates and overall survival. Participants will receive either ZL-1310 as a single drug or Investigators Choice Therapy, which includes options like Topotecan or Amrubicin. The study is randomized and open-label, meaning participants are assigned to one of these treatments without masking. Treatment effects will be monitored over up to 30 months, with evaluations conducted regularly throughout this period. During the trial, participants will undergo tumor biopsies or provide archived tumor tissue samples at screening. They will be assessed for measurable disease and monitored for response using standard criteria RECIST v1.1, as well as quality of life measures. Safety will be tracked by recording treatment-related side effects and adverse events. The study includes comprehensive evaluations of survival, response duration, progression-free survival, and central nervous system responses, with participation lasting up to nearly three years.

Age: 18Years +All GendersPhase 3
165 locations
E

Actively Recruiting

Crohns disease is a long-term condition causing inflammation that can affect any part of the gut. This research aims to evaluate the safety and effectiveness of TAK-279 compared to a placebo in adults with moderately to severely active Crohns disease. The main goal is to find out if three different doses of TAK-279 can reduce bowel inflammation and ulcers after 12 weeks of treatment using endoscopy to assess the bowel. Participants will be randomly assigned to receive one of three doses of TAK-279 or a placebo capsule, taken orally. The treatment period lasts for 52 weeks, or 1 year. The study includes an initial induction phase with treatment assignment and a 4-week safety follow-up phase after completing treatment. The trial is conducted at multiple centers worldwide and involves about 268 participants. Participants will visit the study clinic 15 times during the study. During these visits, researchers will conduct endoscopies and use scores like the Simple Endoscopic Score for Crohns Disease SES-CD and the Crohns Disease Activity Index CDAI to measure inflammation and disease activity. Quality of life and fatigue will also be assessed using questionnaires. Safety and tolerability will be monitored throughout the study and during the follow-up period, with total participation lasting about 60 weeks.

Age: 18Years - 75YearsAll GendersPhase 2
201 locations
R

Actively Recruiting

Researchers are evaluating a treatment for advanced breast cancer characterized by positive estrogen receptors, negative HER2 status, and mutations in the ESR1 gene. This study focuses on patients whose cancer has progressed despite prior endocrine therapy and treatment with CDK46 inhibitors. The main goal is to assess how well the combination of elacestrant and everolimus works compared to elacestrant alone in controlling the disease. Participants will be randomly assigned to one of two groups. One group receives daily oral doses of elacestrant and everolimus, while the other receives elacestrant plus a placebo resembling everolimus. Treatment continues in 28-day cycles until the disease progresses, unacceptable side effects occur, or other reasons lead to stopping treatment. After stopping, patients enter a follow-up period lasting up to 12 months where survival and new treatments are tracked every three months. During the study, patients will undergo tumor assessments, clinical evaluations, and quality-of-life questionnaires. Researchers will monitor treatment effects, side effects, and changes in health status. Safety is closely observed through regular tests including blood work and heart function monitoring. The total participation duration may extend up to about a year from treatment start to study completion.

Age: 18Years +All GendersPhase 3
104 locations
P

Actively Recruiting

Researchers are conducting a phase 3 clinical trial comparing two treatment combinations for adults with ER-positive, HER2-negative advanced breast cancer who have not received prior systemic anti-cancer treatment for this condition. The study aims to evaluate the effectiveness and safety of palazestrant combined with ribociclib versus letrozole combined with ribociclib. Participants include men and women with locally advanced or metastatic breast cancer not suitable for curative therapy. Participants are randomly assigned to one of two groups. One group receives palazestrant 90 mg once daily, ribociclib 600 mg once daily on days 1-21 of a 28-day cycle, and a placebo matching letrozole daily. The other group receives letrozole 2.5 mg once daily, ribociclib 600 mg once daily on days 1-21 of a 28-day cycle, and a placebo matching palazestrant daily. Treatment cycles repeat every 28 days, and the study includes approximately 1,000 participants worldwide. During the study, participants will be monitored for disease progression and overall survival, with primary measurements taken from the date of randomization until disease progression or death, estimated up to 3.5 years. Safety, drug levels, and patient-reported health outcomes will be assessed regularly. The trial includes long-term follow-up for up to 5.5 years to evaluate overall survival. Participants will have scheduled visits for assessments and monitoring throughout their involvement in the trial.

Age: 18Years +All GendersPhase 3
200 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of adagrasib MRTX849 alone and combined with pembrolizumab in patients with advanced or metastatic non-small cell lung cancer NSCLC who have a KRAS G12C mutation. The study includes both Phase 2 and Phase 3 portions, focusing on patients eligible for first-line treatment with varying levels of PD-L1 expression. The trial compares adagrasib combined with pembrolizumab to pembrolizumab alone in patients with high PD-L1 expression. In Phase 2, patients are divided into three groups based on PD-L1 TPS scores two groups with scores below 1% receive either adagrasib monotherapy or adagrasib plus pembrolizumab, and one group with scores of 1% or higher receives the combination. Phase 3 randomizes patients with PD-L1 TPS of 50% or higher to receive either adagrasib plus pembrolizumab or pembrolizumab alone. Adagrasib is taken orally twice daily, while pembrolizumab is given intravenously every three weeks. Participants undergo regular assessments including brain imaging, tumor measurements, and quality of life questionnaires. Researchers monitor treatment effects, safety, drug levels in blood, and lung cancer symptoms over periods of up to 22 months in Phase 2 and 36 months in Phase 3. The study also evaluates progression-free survival, response duration, and other outcomes to understand the treatments impact.

Age: 18Years +All GendersPhase 2Phase 3
770 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of combining gedatolisib with palbociclib and endocrine therapy compared to endocrine therapy with ribociclib for treating adults with locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer. This Phase 3, open-label, randomized clinical trial focuses on patients who are either endocrine-resistant or endocrine-sensitive based on their cancer progression and prior treatments. Participants will be assigned based on endocrine sensitivity status to one of two studies. Study 1 includes patients with endocrine-resistant cancer receiving either gedatolisib plus palbociclib and fulvestrant or ribociclib with fulvestrant. Study 2 includes endocrine-sensitive patients treated with gedatolisib plus palbociclib and letrozole or ribociclib plus letrozole. Gedatolisib is given intravenously once weekly for three weeks followed by a week off. Palbociclib and ribociclib are taken orally on days 1 to 21 of each 28-day cycle. Fulvestrant is administered by intramuscular injection every 2 to 4 weeks, while letrozole is taken orally daily. Throughout the study, participants undergo regular assessments including scans and laboratory tests to monitor disease progression and safety. Researchers measure outcomes such as progression-free survival, overall survival, response rates, duration and time to response, clinical benefits, quality of life, and adverse events over approximately 48 months. The trial includes screening to confirm eligibility and ongoing monitoring during and after treatment to evaluate the treatments effects and safety.

Age: 18Years +All GendersPhase 3
239 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of two drug combinations for treating patients with hormone receptor-positive, HER2-negative advanced breast cancer that has a PIK3CA mutation. This phase 3, open-label, global study compares RLY-2608 zovegalisib plus fulvestrant against capivasertib plus fulvestrant following disease recurrence or progression after prior treatment with a CDK46 inhibitor. The study focuses on patients whose cancer has advanced locally or metastasized and have specific genetic mutations influencing treatment response. Participants will receive one of two treatment combinations zovegalisib taken orally twice daily together with fulvestrant given by intramuscular injection on specified days in a 28-day cycle, or capivasertib taken orally twice daily on an intermittent weekly schedule combined with the same fulvestrant regimen. Treatment cycles repeat every 28 days. The study will monitor and compare these combinations over several months to assess outcomes. Throughout the study, participants will undergo regular assessments including imaging scans to measure cancer progression, blood tests to monitor drug levels, and questionnaires to evaluate quality of life. Researchers will track progression-free survival, overall survival, response rates, duration of response, clinical benefit, and safety profiles. The study duration may extend up to approximately 77 months, with ongoing monitoring of health status and adverse events to gather comprehensive data on treatment impact.

Age: 18Years +All GendersPhase 3
243 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness of saruparib AZD5305 combined with camizestrant compared to physicians choice of CDK46 inhibitors plus endocrine therapy in patients with BRCA1, BRCA2, or PALB2 mutated, hormone receptor-positive, HER2-negative advanced breast cancer. This phase III study aims to determine which treatment better controls disease progression in this specific patient population. Participants will be randomly assigned to one of four treatment groups saruparib plus camizestrant physicians choice CDK46 inhibitor plus endocrine therapy physicians choice CDK46 inhibitor plus camizestrant or saruparib plus physicians choice endocrine therapy. Treatments are given orally or by injection as appropriate and will continue until the disease progresses, unacceptable side effects occur, or participants choose to stop treatment. During the study, participants will have regular assessments to evaluate disease progression, survival, response to treatment, and quality of life. Researchers will monitor drug levels in the blood and collect tissue samples to support diagnostic development. The study may last up to several years, with ongoing safety and efficacy evaluations to understand the impact of these treatments on advanced breast cancer.

Age: 18Years +All GendersPhase 3
306 locations
R

Actively Recruiting

Researchers are evaluating how well and safely a new drug called visugromab works in people with advanced cancers that cause unintended weight loss, known as cancer-associated cachexia. This trial aims to find out if visugromab helps participants regain weight, improve appetite, and increase physical activity compared to a placebo. The study is a randomized, double-blind phase 23 trial sponsored by CatalYm GmbH. Participants receive one of several doses of visugromab or a placebo through a drip into a vein once every four weeks. The study compares low, medium, and high doses of visugromab against a placebo over the course of treatment. The main treatment period focuses on evaluating changes in body weight and appetite at 12 weeks. During the study, participants visit the hospital or clinic every four weeks for infusions and checkups. Researchers monitor medical problems, physical activity, and weight changes. The primary outcomes measured are the change in body weight and appetite after 12 weeks of treatment. The study is expected to continue through 2030, with ongoing safety and efficacy assessments throughout the participation period.

Age: 18Years +All GendersPhase 2Phase 3
79 locations